Balance Sheet
Accounts PayablesAccumulated ExpensesAssetsCapital LeasesCash & Current InvestmentsCash & EquivalentsCommon EquityCurrent AssetsCurrent LeasesLiabilities and Shareholders EquityLong-Term InvestmentsNon-Current AssetsOperating LeasesOther Accumulated ExpensesOther Non-Current AssetsOther Non-Current LiabilitiesPayablesPreferred Stock LiabilitiesPrepaid AssetsProperty, Plant & Equipment (Net)Retained EarningsShareholder's EquityShort-term InvestmentsTotal Current LiabilitiesTotal LiabilitiesTotal Non-Current LiabilitiesTreasury Shares
Cash Flow Statement
Daily Values
Growth Metrics
Income Statement
Others
Ratios

Evommune (EVMN) Accumulated Expenses (2024 - 2025)

Evommune (EVMN) has disclosed Accumulated Expenses for 2 consecutive years, with $4.9 million as the latest value for Q4 2025.

  • On a quarterly basis, Accumulated Expenses fell 26.68% to $4.9 million in Q4 2025 year-over-year; TTM through Dec 2025 was $4.9 million, a 26.68% decrease, with the full-year FY2025 number at $4.9 million, down 26.68% from a year prior.
  • Accumulated Expenses was $4.9 million for Q4 2025 at Evommune, up from $2.9 million in the prior quarter.
  • In the past five years, Accumulated Expenses ranged from a high of $6.7 million in Q4 2024 to a low of $2.9 million in Q3 2025.